Need help with B2B Marketing?
Let the smarketers’ team drive your pipeline with data-led campaigns and AI-powered growth strategies.
A SaaS ABM playbook is useless for a CDMO. The sales cycle is 18 months, not 9. The buying committee has regulatory officers and quality assurance directors, not product managers. The win is a master services agreement worth $20M to $80M, not a $50K ARR subscription. The evaluation is a site audit, not a free trial.
Life sciences marketing leaders often inherit ABM templates built for tech and try to force-fit them. The result: high marketing spend, low pipeline impact, and a frustrated BD team. The playbook has to be rebuilt for the sector.
Enterprise CDMO sales cycles average 14 to 22 months for strategic partnerships (Nice Insight CDMO Benchmark 2025). Biopharma buying committees average 8 to 12 stakeholders per award decision (ISR Reports 2025).
Why standard ABM does not fit
Four structural differences between SaaS ABM and life sciences ABM:
- Cycle length. 18 months vs 6 to 9 months for SaaS. Weekly cadence becomes quarterly. Tactical campaigns become year-long relationship plans.
- Scientific credibility is the currency. A biopharma buyer will not engage with a vendor that cannot hold a technical conversation at principal scientist level. Marketing collateral has to be scientifically defensible.
- RFP-driven procurement. Awards happen through structured RFPs with 6 to 12 competitors. The marketing job is to get invited to the RFP, not to pitch directly to buyers.
- Low account count, high account value. 50 to 200 enterprise biopharma accounts globally. Each account is worth $20M to $500M over 5 years. 1:1 ABM is the baseline, not the aspiration.
The 4-phase ABM architecture for life sciences
Phase 1: Scientific authority building (months 1 to 6)
Before you can sell, you need scientific presence. That means: peer-reviewed publications or method papers, speaker slots at AAPS, DCAT, CPhI, ACS BIOT, or equivalent, participation in working groups (USP, BioPhorum, ISCT, PDA), and thought leadership from named scientific officers. This is not optional. Biopharma procurement screens for it.
Timeline: 6 to 12 months to build initial presence, ongoing investment thereafter. Budget: meaningful; this is a people-led programme, not a content marketing tactic.
Phase 2: Named account nurture (months 3 to 18, runs in parallel)
Identify the 50 to 200 accounts you want to win over 3 years. For each, map the 8 to 12 stakeholders. For each stakeholder, define a content and engagement plan that runs quarterly, not monthly.
Engagement cadence: 1 scientific content touch per quarter, 1 executive round table invitation per year, 1 field sales touch per quarter, 1 event interaction per year (conference, user group, advisory meeting). Total: 8 to 10 meaningful touches per stakeholder per year. Over 18 months, that is 12 to 15 touches. The cumulative effect is what drives RFP invitations.
Phase 3: RFP readiness and response (months 12 to 24)
The goal of phases 1 and 2 is to get onto the RFP shortlist. Phase 3 is the RFP response motion. This is a BD-led phase with strong marketing support: case studies, facility tour videos, regulatory track record, quality metrics, financial stability evidence, comparable program references.
RFP win rate is the leading metric here. Industry average is 15 to 22%. Teams with strong phases 1 and 2 see 35 to 55%.
Phase 4: Alliance management (post-contract, ongoing)
The contract is the start of the real relationship. Alliance management (contract governance, quarterly business reviews, program expansion opportunities) is where 60 to 80% of CDMO revenue is protected and grown. Marketing supports with executive briefings, innovation round tables, and expansion content.
SCIENTIFIC PRESENCE IS THE MOAT. CDMOS AND CROS WITHOUT PUBLISHED METHODS, CONFERENCE SPEAKER SLOTS, AND NAMED SCIENTIFIC OFFICERS ARE INVISIBLE TO ENTERPRISE BIOPHARMA BUYERS REGARDLESS OF MARKETING SPEND. PHASE 1 IS THE PREREQUISITE, NOT A PHASE 4 NICE-TO-HAVE.
What content actually works
From 18 months of benchmarking across life sciences ABM campaigns, the content types with highest engagement from biopharma buying committees:
- Method papers and technical briefs (authored by named scientists). 2. Regulatory track record summaries (inspection history, CAPA trends). 3. Case studies on comparable programs (anonymised but specific). 4. Executive round table recordings (peer-led discussions). 5. Facility tour videos with QA commentary. 6. ROI models for dual-sourcing or technology transfer decisions.
Generic ‘thought leadership’ blog posts rank poorly. Buyers have no time for content that does not speak at their technical level.
Measurement for long-cycle sectors
MQL and SQL are meaningless at 18-month cycles. The metrics that matter:
- Account penetration score. % of the 8 to 12 stakeholders at target accounts who have engaged meaningfully in the last 6 months. Target: 50%+ at year 1, 75%+ at year 2.
- RFP invitation rate. % of target accounts that invite you to participate in RFPs per year. Target: 20%+ at year 1, 40%+ at year 2.
- Scientific content consumption depth. Average content items consumed per stakeholder per year. Target: 3+ per stakeholder at year 1.
- Program expansion rate (post-win). % of existing contracts expanded into new programs or sites per year.
The team structure
A functioning life sciences ABM programme needs 5 roles: Scientific Content Lead (PhD-level, authors and edits all technical content), Marketing Director (orchestration and campaigns), Field Marketing Manager (events and account-specific programs), Digital Marketing Manager (web, email, paid), and BD partner (sales orchestration). Below 5, the programme is under-resourced for the account count and cycle length.
Book a life sciences ABM strategy call
Frequently Asked Questions
Why are CDMO and CRO sales cycles so long?
Who sits on a typical biopharma buying committee for CDMO services?
Champion (internal advocate), Economic Buyer (budget holder), Technical Evaluator (architecture fit), User/Operator (day-to-day usage), and Compliance or Procurement (risk clearance). Everyone else is secondary.
Is traditional ABM even appropriate for this sector?
Yes, with adjustments. The account list is smaller (50 to 200 enterprise biopharma), the content is deeply technical and scientifically credible, the cycle is longer, and the sales motion is relationship-first, not demo-first. The ABM principles hold; the tactics shift.
